1071 related articles for article (PubMed ID: 26697765)
1. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
Woodworth TG; den Broeder AA
Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765
[TBL] [Abstract][Full Text] [Related]
2. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg JE; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Ann Rheum Dis; 2017 Jun; 76(6):960-977. PubMed ID: 28264816
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
[TBL] [Abstract][Full Text] [Related]
5. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
[TBL] [Abstract][Full Text] [Related]
6. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
7. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen JS; Landewé RBM; Bergstra SA; Kerschbaumer A; Sepriano A; Aletaha D; Caporali R; Edwards CJ; Hyrich KL; Pope JE; de Souza S; Stamm TA; Takeuchi T; Verschueren P; Winthrop KL; Balsa A; Bathon JM; Buch MH; Burmester GR; Buttgereit F; Cardiel MH; Chatzidionysiou K; Codreanu C; Cutolo M; den Broeder AA; El Aoufy K; Finckh A; Fonseca JE; Gottenberg JE; Haavardsholm EA; Iagnocco A; Lauper K; Li Z; McInnes IB; Mysler EF; Nash P; Poor G; Ristic GG; Rivellese F; Rubbert-Roth A; Schulze-Koops H; Stoilov N; Strangfeld A; van der Helm-van Mil A; van Duuren E; Vliet Vlieland TPM; Westhovens R; van der Heijde D
Ann Rheum Dis; 2023 Jan; 82(1):3-18. PubMed ID: 36357155
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
9. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
[TBL] [Abstract][Full Text] [Related]
10. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
Mota LMHD; Kakehasi AM; Gomides APM; Duarte ALBP; Cruz BA; Brenol CV; de Albuquerque CP; Castelar Pinheiro GDR; Laurindo IMM; Pereira IA; Bertolo MB; Ubirajara Silva de Souza MPG; de Freitas MVC; Louzada-Júnior P; Xavier RM; Giorgi RDN
Adv Rheumatol; 2018 May; 58(1):2. PubMed ID: 30657071
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Kerschbaumer A; Sepriano A; Bergstra SA; Smolen JS; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Landewé RBM
Ann Rheum Dis; 2023 Jan; 82(1):95-106. PubMed ID: 36368906
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
13. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; Van Hoogstraten H; Mangan E; Carita P; Huynh TM
RMD Open; 2019; 5(1):e000798. PubMed ID: 30886733
[TBL] [Abstract][Full Text] [Related]
15. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
Smolen JS; Landewé R; Breedveld FC; Buch M; Burmester G; Dougados M; Emery P; Gaujoux-Viala C; Gossec L; Nam J; Ramiro S; Winthrop K; de Wit M; Aletaha D; Betteridge N; Bijlsma JW; Boers M; Buttgereit F; Combe B; Cutolo M; Damjanov N; Hazes JM; Kouloumas M; Kvien TK; Mariette X; Pavelka K; van Riel PL; Rubbert-Roth A; Scholte-Voshaar M; Scott DL; Sokka-Isler T; Wong JB; van der Heijde D
Ann Rheum Dis; 2014 Mar; 73(3):492-509. PubMed ID: 24161836
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
18. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Chiu YM; Chen DY
Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
[No Abstract] [Full Text] [Related]
19. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
